Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Blood (2025) 146 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2025-4198

Published: 2025

Journal Articles

Longitudinal and integrated analysis of oral and stool microbiome in allogeneic hematopoietic cell transplantation recipients.

Ronald Siebenaler, E. Anders Kiledal, Marcus Geer, John Magenau, Attaphol Pawarode, Sarah Anand, Monalisa Ghosh, John Maciejewski, Darren King, Sung Choi, Gregory Yanik, Pavan Reddy, Mary Riwes

Blood (2025) 146 (Supplement 1): 4225.

https://doi.org/10.1182/blood-2025-4225

Published: 2025

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Blood (2025) 146 (Supplement 1): 818.

https://doi.org/10.1182/blood-2025-818

Published: 2025

Journal Articles

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Attaphol Pawarode, MD, Steven Goldstein, MD, Daniel R. Couriel, MD, Thomas Braun, PhD, John M. Magenau, MD, Mary Mansour Riwes, DO, Brian Parkin, Vedran Radojcic, MD, David Frame, PharmD, Sung Choi, MD, James Connelly, MD, John E. Levine, MD MS, Gregory A. Yanik, MD, Pavan Reddy, MD

Blood (2015) 126 (23): 1907.

https://doi.org/10.1182/blood.V126.23.1907.1907

Published: 2015

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

Host-derived CD8 + dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation

Tomomi Toubai, Yaping Sun, Gary Luker, Jun Liu, Kathryn E. Luker, Isao Tawara, Rebecca Evers, Chen Liu, Nathan Mathewson, Chelsea Malter, Evelyn Nieves, Sung Choi, Kenneth M. Murphy, Pavan Reddy

Blood (2013) 121 (20): 4231–4241.

https://doi.org/10.1182/blood-2012-05-432872

Published: 2013

Includes: Supplemental data

Journal Articles

Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.

Gregory A. Yanik, John M. Magenau, Shin Mineishi, Attaphol Pawarode, Keith Alangaden, Edward M. Peres, Steven Goldstein, John E. Levine, Sung Choi, Carrie L Kitko, Moshe Talpaz, MD, Daniel Couriel

Blood (2012) 120 (21): 3119.

https://doi.org/10.1182/blood.V120.21.3119.3119

Published: 2012

Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Blood (2011) 118 (15): 4258–4264.

https://doi.org/10.1182/blood-2011-06-358010

Published: 2011

Includes: Supplemental data

Journal Articles

Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a

Tint Lwin, Jianhong Lin, Yong Sung Choi, Xinwei Zhang, Lynn C. Moscinski, Kenneth L. Wright, Eduardo M. Sotomayor, William S. Dalton, Jianguo Tao

Blood (2010) 116 (24): 5228–5236.

https://doi.org/10.1182/blood-2010-03-275925

Published: 2010

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Shin Mineishi, MD, John Magenau, MD, Hiromi Tobai, MD, Attaphol Pawarode, MD, Edward M. Peres, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Harry P Erba, MD, PhD, Lisa Kujawski, MD, Gregory Yanik, MD, James Ferrara, MD, John E. Levine, MD, MS

Blood (2010) 116 (21): 35.

https://doi.org/10.1182/blood.V116.21.35.35

Published: 2010

Journal Articles

Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas

Tint Lwin, MD, PhD, Jian-Hong Lin, MD, Yong Sung Choi, MD, PhD, Xinwei Zhang, MD, Lynn Moscinski, MD, Kenneth Wright, PhD, Eduardo M. Sotomayor, MD, William Dalton, PhD, MD, Jianguo Tao, MD, PhD

Blood (2010) 116 (21): 3118.

https://doi.org/10.1182/blood.V116.21.3118.3118

Published: 2010

Journal Articles

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Blood (2010) 116 (21): 675.

https://doi.org/10.1182/blood.V116.21.675.675

Published: 2010

Journal Articles

Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.

Jianhong Lin, M.D, Tint Lwin, MD, PhD, Wayne Tam, MD, PhD, Jian-Jun Zhao, Luis Crespo, Yong Sung Choi, Xinwei Zhang, Victoria Tannenbaum, Eduardo M. Sotomayor, MD, Lynn C. Moscinski, MD, William S. Dalton, PhD, MD, Ken Wright, PhD, Jianguo Tao, MD, PhD

Blood (2010) 116 (21): 3853.

https://doi.org/10.1182/blood.V116.21.3853.3853

Published: 2010

Journal Articles

Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes.

Yasser Khaled, MD, Sung Choi, MD, David A Hanauer, MD, MS, Pavan Reddy, MD

Blood (2009) 114 (22): 3324.

https://doi.org/10.1182/blood.V114.22.3324.3324

Published: 2009

Journal Articles

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Blood (2009) 114 (22): 43.

https://doi.org/10.1182/blood.V114.22.43.43

Published: 2009

Journal Articles

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

Corey Cutler, Kristen Stevenson, Haesook T. Kim, Paul Richardson, Vincent T. Ho, Erica Linden, Carolyn Revta, Ruth Ebert, Diane Warren, Sung Choi, John Koreth, Philippe Armand, Edwin Alyea, Shelly Carter, Mary Horowitz, Joseph H. Antin, Robert Soiffer

Blood (2008) 112 (12): 4425–4431.

https://doi.org/10.1182/blood-2008-07-169342

Published: 2008

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

Journal Articles

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Sophie Paczesny, MD, PhD., John E. Levine, MD, Jason Hogan, PhD., Jeffrey Crawford, Thomas Braun, PhD, Hong Wang, PhD., Vitor Faca, PhD, Qing Zhang, Sharon Pitteri, PHD, Alice Chin, Sung Choi, MD, Carrie Kitko, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Shin Mineishi, MD, Joel Whitfield, Dawn Jones, RN, Samir Hanash, MD, PhD, James L.M. Ferrara, MD

Blood (2008) 112 (11): 716.

https://doi.org/10.1182/blood.V112.11.716.716

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.

Longitudinal and integrated analysis of oral and stool microbiome in allogeneic hematopoietic cell transplantation recipients.

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Host-derived CD8 + dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation

Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.

Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes.

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only